I might have missed this but in the recent ASX announcement announcing the relationship with Coviu, no reference is made to whether or not the agreement provides exclusivity.
Given Coviu intend to enter the US market does one would assume exclusivity of use is guaranteed? What would be the competitive advantage for Coviu otherwise?
If it is guaranteed could one presume all other potential deals with US suitors would be off the table?
Coviu & ResApp, page-12
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #